GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Abaxis Inc (NAS:ABAX) » Definitions » Cash Conversion Cycle

Abaxis (Abaxis) Cash Conversion Cycle : 151.47 (As of Mar. 2018)


View and export this data going back to 1992. Start your Free Trial

What is Abaxis Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Abaxis's Days Sales Outstanding for the three months ended in Mar. 2018 was 59.49.
Abaxis's Days Inventory for the three months ended in Mar. 2018 was 129.19.
Abaxis's Days Payable for the three months ended in Mar. 2018 was 37.21.
Therefore, Abaxis's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2018 was 151.47.


Abaxis Cash Conversion Cycle Historical Data

The historical data trend for Abaxis's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abaxis Cash Conversion Cycle Chart

Abaxis Annual Data
Trend Mar09 Mar10 Mar11 Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 168.59 148.07 162.15 168.01 171.06

Abaxis Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 167.97 173.68 170.48 161.87 151.47

Competitive Comparison of Abaxis's Cash Conversion Cycle

For the Diagnostics & Research subindustry, Abaxis's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abaxis's Cash Conversion Cycle Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Abaxis's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Abaxis's Cash Conversion Cycle falls into.



Abaxis Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Abaxis's Cash Conversion Cycle for the fiscal year that ended in Mar. 2018 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=66.18+136.57-31.69
=171.06

Abaxis's Cash Conversion Cycle for the quarter that ended in Mar. 2018 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=59.49+129.19-37.21
=151.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abaxis  (NAS:ABAX) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Abaxis Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Abaxis's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Abaxis (Abaxis) Business Description

Traded in Other Exchanges
N/A
Address
Abaxis Inc manufactures point-of-care blood analysis instruments and consumables for medical and veterinary care providers. The medical segment sells Piccolo Chemistry Analyzers, which can provide results about a blood sample in 12 minutes, and related reagents to physicians, hospitals, pharmacies, and other healthcare providers. The veterinary segment generates the majority of the firm's total revenue and sells products to animal hospitals, veterinary clinics, and private research laboratories. Products in this segment include the VetScan VS2 chemistry analyzer, animal-specific reagents, and rapid tests for canine and feline diseases. The vast majority of the firm's revenue comes from North America and Europe.
Executives
Richard Bastiani director C/O ABAXIS INC, 3240 WHIPPLE RD, UNION CITY CA 94587
Taylor Dean Ross Jr officer: CFO and VP of Finance C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Clinton Severson director, officer: CEO & Board Chairman C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Michael D Casey director ALLOS THERAPEUTICS, INC., 11080 CIRCLEPOINT ROAD, SUITE 200, WESTMINSTER CO 80020